RESEARCH ARTICLE

Enterovirus 71 seroepidemiology in Taiwan in 2017 and comparison of those rates in 1997, 1999 and 2007

Jian-Te Lee, Ting-Yu Yen, Wei-Liang Shih, Chun-Yi Lu, Ding-Ping Liu, Yi-Chuan Huang, Luan-Yin Chang, Li-Min Huang, Tzou-Yien Lin

Abstract

Background
During recent 20 years, enterovirus 71 (EV71) has emerged as a major concern among children, particularly in the Asia-Pacific region. To understand current EV71 serostatus, to find risk factors associated with EV71 infection and to establish future EV71 vaccine policy, we performed a seroepidemiology study in Taiwan in 2017.

Methods
After informed consent was obtained, we enrolled preschool children, 6–15-year-old students, 16–50-year-old people. They received a questionnaire and a blood sample was collected to measure the EV71 neutralization antibody.

Results
Altogether, 920 subjects were enrolled with a male-to-female ratio of 1.03. The EV71 seropositive rate was 10% (8/82) in infants, 4% (6/153) in 1-year-old children, 8% (7/83) in 2-year-old children, 8% (13/156) in 3–5-year-old children, 31% (38/122) in 6–11-year-old primary school students, 45% (54/121) in 12–15-year-old high school students and 75% (152/203) in 16-50-year-old people. Risk factors associated with EV71 seropositivity in preschool children were female gender, having siblings, more siblings, and contact with herpangina or hand-foot-and-mouth disease. The risk factor with EV71 seropositivity in 16–50-year-old people was having children in their families in addition to older age (p<0.001). Compared with the rates in 1997, 1999 and 2007, the rates in children were significantly lower in 2017.
Conclusion
EV71 seropositive rates were very low, at 4% to 10%, in preschool children and not high, at 31%, in primary school students. Preschool children are highly susceptible and need EV71 vaccine most.

Introduction
Enterovirus 71 (EV71) was first isolated in California, USA in 1969 [1]. Since then, EV71 emerged in various regions throughout the world [2–7]. Large-scale outbreaks with frequent central nervous system (CNS)-complicated cases and deaths were found in Bulgaria, Hungary, Malaysia, Taiwan, Vietnam, Brunei, China and Cambodia [2–8]. An EV71 epidemic swept Taiwan in 1998, which caused 405 severe cases and 78 deaths [8–12]. After the epidemic, multiple and real-time national enterovirus surveillance systems were established by the Taiwan Centers for Disease Control, including viral lab network; outpatient, inpatient, and emergency room visits for hand-foot-and-mouth disease (HFMD) and/or herpangina (HA); and mandatory notification of enterovirus severe cases [13–16]. After the first EV71 epidemic in 1998, EV71 cases occurred again in 2000–2001, 2005, 2008, and 2012 based on the surveillance data [15–17]. There seems to be a nationwide EV71 epidemic every 3 to 5 years. In addition to Taiwan, EV71 has emerged as a major concern among children in the Asia-Pacific region during recent 20 years [4,6,7].

After several epidemics, there is an urgent need to understand the current EV71 serostatus of high-risk groups and the high transmission population to predict future epidemics and to establish future EV71 vaccine policy [18]. In addition, we can compare the seroepidemiology in different years to determine the temporal change in the EV71 endemics in Taiwan. We thus performed this seroepidemiology study.

Methods
Study subjects
The Institutional Review Board of the National Taiwan University Hospital approved this study. After written informed consent was obtained from parents or guardians of children, we enrolled preschool children, 6–11-year-old primary school students and 12–15-year-old high school students in the northern (Taipei City), eastern (Hualien County), western (Yunlin County) and southern (Kaohsiung City) regions of Taiwan between May and November 2017. Community-dwelling 16–50-year-old healthy people were also enrolled in the four different regions of Taiwan after their own written informed consent was obtained. Participants received a questionnaire, and a blood sample was collected and submitted for measuring the EV71 neutralization antibody.

Data collection for the serosurvey
The questionnaire solicited demographic data, residential area, number of children and adults in a family, vaccination history, past history of HFMD and/or HA, intrafamilial or outside contact with HFMD and/or HA cases, family members with HFMD and/or HA, classmates or neighbors with HFMD and/or HA, sources of drinking water, employment of a babysitter, enrollment in a kindergarten or childcare center, and breastfeeding during infancy. No EV71 vaccine is licensed in Taiwan up to now. Contact with HFMD and/or HA cases was defined as...
kissing, hugging, shaking hands, sharing food, or playing with children who had HFMD and/or HA. All interviewers were trained, and contact history information was collected from several family members to minimize recall bias. The questionnaires for preschool children, students and adults are listed in the supplementary files (S1, S2 and S3 Files).

**Laboratory methods for the EV71 neutralizing antibody**

The serum neutralizing antibody response is the major indicator of EV71 protective immunity. The neutralizing antibody test of EV71 followed the standard protocol of a neutralization test. Serum samples were heat-treated for 30 minutes at 56°C, serially diluted and mixed with 100 50% tissue culture-infective doses (TCID₅₀) of the EV71 TW/2272/98 strain (GenBank accession number AF119795), and incubated for 2 hours at 37°C. Thereafter, rhabdomyosarcoma cells were added into each reaction well and incubated at 37°C in 5% CO₂ incubator. Each plate included a cell control, serum control, and virus back-titration. The cytopathic effect was monitored from 5 to 6 days after incubation, and the serotiter was determined when the cytopathic effect was observed in one TCID₅₀ of the virus back-titration. Seropositivity was defined as a serotiter ≥ 8. For details, please see http://dx.doi.org/10.17504/protocols.io.7pwhmpe.

**Comparison of EV71 serostatus among 1997, 1999, 2007 and 2017**

We previously performed EV71 seroepidemiology studies in 1997, 1999, and 2007, which were conducted by Dr. Luan-Yin Chang and Dr. Tzou-Yien Lin [19]. The method for neutralization antibody measurement was the same. We thus compared the age-specific seropositive rates among different years.

**Statistical analyses**

We analyzed the data with the SAS statistical software (version, SAS Institute, Cary, North Carolina). We used Student’s t-test for continuous data and chi-squared tests for categorical data. A p value <0.05 indicated a statistical significance.

**Results**

**Demography and EV71 serostatus in 2017**

We conducted nationwide recruitment from urban and rural regions, as Table 1 shows. Taipei City and Kaohsiung City, two metropolitan areas, are located in the northern and southern regions of Taiwan, whereas Hualien County and Yunlin County, two rural areas, are located in the eastern and western regions of Taiwan.

In total, 920 subjects were enrolled with a male-to-female ratio of 1.03. Direct standardization method was applied to calculate age-region standardized seroprevalence for male and female, using the population of Taipei City, Hualien County, Yunlin County and Kaohsiung City in 2017 as the standard population. Overall, females had significantly greater seropositive rates than males, as Fig 1 shows (p = 0.01). The EV71 seropositive rate was 10% (8/82) in infants, 4% (6/153) in 1-year-old children, 8% (7/83) in 2-year-old children, 8% (13/156) in 3–5-year-old children, 31% (38/122) in 6–11-year-old primary school students, 45% (54/121) in 12–15-year-old high school students, 80% (97/122) in 16-50-year-old women and 68% (55/81) in 16-50-year-old men in 2017.

There was significant difference of seropositive rates among preschool and primary student children between the rural areas and metropolitan areas, as Table 1 shows. The seropositive rates of 3–5-year-old kindergarteners and 6–11-year-old primary school children were
significantly greater in rural areas (Hualien County and Yunlin County) than in metropolitan areas (Taipei City and Kaohsiung City). Among the four regions, there were no significant differences in the age and gender of the enrolled people, but the family size was larger (4.4 ± 1.8 vs. 3.9 ± 1.7, p < 0.001) and the rate of drinking spring or well water was significantly greater (18% vs. 9%, p < 0.05) in rural areas than in metropolitan areas.

### Table 1. Age-specific EV71 seropositive rates in four different regions of Taiwan in 2017.

| Age in years | Overall | Taipei (N) | Kaohsiung (S) | Yunlin (W) | Hualien (E) | p value |
|--------------|---------|------------|---------------|------------|-------------|---------|
| <1           | 10% (8/82) | 10% (3/29) | 5% (1/21)     | 16% (4/25) | 0% (0/7)    | 0.48    |
| 1            | 4% (6/153) | 10% (3/31) | 2% (1/45)     | 0% (0/32) | 4% (2/45)   | 0.22    |
| 2            | 8% (7/83)  | 14% (4/28) | 0% (0/9)      | 4% (1/23) | 9% (2/23)   | 0.46    |
| 3–5          | 8% (13/156) | 4% (3/70)  | 0% (0/26)     | 14% (4/29) | 19% (6/31)  | 0.02    |
| 6–11         | 31% (38/122) | 20% (6/30) | 21% (7/34)    | 37% (10/27) | 48% (15/31) | 0.04    |
| 12–15        | 45% (54/121) | 26% (8/31) | 54% (15/28)   | 45% (14/31) | 55% (17/31) | 0.08    |
| 16–50        | 75% (152/203) | 73% (37/51) | 63% (32/51)   | 84% (42/50) | 80% (41/50) | 0.07    |

The p value was measured by chi-squared test. N denotes the northern region, W is the western region, S is the southern region, and E is the eastern region. Taipei City and Kaohsiung City are metropolitan areas, whereas Hualien County and Yunlin County are rural areas.

[https://doi.org/10.1371/journal.pone.0224110.t001](https://doi.org/10.1371/journal.pone.0224110.t001)

#### Fig 1. Age-specific EV71 serostatus between males and females in 2017. Overall, females had significantly greater seropositive rates than males (p = 0.01).

[https://doi.org/10.1371/journal.pone.0224110.g001](https://doi.org/10.1371/journal.pone.0224110.g001)
Table 2 shows risk factors associated with EV71 seropositivity in preschool children aged less than 6 years old and significant risk factors were female gender, having siblings, more siblings, and contact with HFMD and/or HA. Residential areas, breast feeding, vaccination history, and source of drinking water did not affect the EV71 seropositivity in preschool children.

**Table 2. Risk factors associated with EV71 seropositivity in preschool children in 2017.**

| Factor                                      | Seropositive (N = 34) | Seronegative (N = 440) | OR, 95% CI   | p value |
|---------------------------------------------|-----------------------|-------------------------|--------------|---------|
| **Sex**                                     |                       |                         |              |         |
| Male                                        | 13 (38.2%)            | 245 (55.7%)             | Ref.         |         |
| Female                                      | 21 (61.8%)            | 195 (44.3%)             | 2.03, (1.00, 4.26) | 0.05    |
| **Age (years)**                             | Mean±SD               |                         |              |         |
| Male                                        | 2.8±1.8               | 2.5±1.6                 |              | 0.45    |
| Female                                      | 2.3±1.5               | 2.3±1.6                 |              |         |
| **Residential area**                        |                       |                         |              |         |
| City                                        | 23 (67.6%)            | 287 (65.2%)             | Ref.         |         |
| Village                                     | 9 (26.5%)             | 113 (25.7%)             | 0.45, (0.45, 2.21) | 0.99    |
| Suburban                                    | 2 (5.9%)              | 35 (8.0%)               | 0.71, (0.16, 3.15) | 0.66    |
| Industrial                                  | 0 (0%)                | 5 (1.1%)                |              |         |
| **Household size**                          | Mean±SD               |                         |              |         |
| Male                                        | 4.1±1.7               | 4.3±1.8                 |              | 0.53    |
| Female                                      | 4.3±1.8               | 4.3±1.8                 |              |         |
| **Sibling**                                 |                       |                         |              |         |
| Male                                        | 6 (17.7%)             | 167 (38.0%)             | Ref.         |         |
| Female                                      | 28 (82.3%)            | 273 (62.0%)             | 2.85, (1.16, 7.04) | 0.02    |
| **History of chronic illness**              |                       |                         |              |         |
| Male                                        | 5 (14.7%)             | 36 (8.2%)               | 1.93, (0.71, 5.30) | 0.19    |
| Female                                      | 33 (97.1%)            | 409 (92.9%)             | 2.50, (0.33, 18.89) | 0.36    |
| **Ever breastfed**                          |                       |                         |              |         |
| Male                                        | 1 (2.9%)              | 31 (7.1%)               | Ref.         |         |
| Female                                      | 25 (73.5%)            | 277 (62.9%)             | 1.64, (0.75, 3.59) | 0.22    |
| **Main source of drinking water**           |                       |                         |              |         |
| Tap water                                   | 19 (55.9%)            | 260 (59.1%)             | Ref.         |         |
| Well water                                  | 0 (0%)                | 2 (0.5%)                | NA           |         |
| Spring                                      | 4 (11.8%)             | 51 (11.5%)              | 1.07, (0.35, 3.29) | 0.90    |
| Others                                      | 11 (32.3%)            | 127 (28.9%)             | 1.19, (0.55, 2.57) | 0.67    |
| **History of HFMD**                         |                       |                         |              |         |
| Male                                        | 22 (64.7%)            | 334 (75.9%)             | Ref.         |         |
| Female                                      | 11 (32.4%)            | 99 (22.5%)              | 1.69, (0.79, 3.60) | 0.18    |
| Unknown                                     | 1 (2.9%)              | 7 (1.6%)                |              |         |
| **History of herpangina**                   |                       |                         |              |         |
| Male                                        | 26 (76.5%)            | 316 (71.8%)             | Ref.         |         |
| Female                                      | 8 (23.5%)             | 110 (25.0%)             | 0.88, (0.39, 2.01) | 0.77    |
| Unknown                                     | 0 (0.0%)              | 14 (3.2%)               |              |         |
| **Family member with history of HFMD and/or herpangina** |     |                         |              |         |
| Male                                        | 20 (58.8%)            | 288 (65.5%)             | Ref.         |         |
| Female                                      | 13 (38.2%)            | 134 (30.4%)             | 1.40, (0.68, 2.89) | 0.37    |
| Unknown                                     | 1 (2.9%)              | 18 (4.1%)               |              |         |
| **Classmates with history of HFMD and/or herpangina** | |                         |              |         |
| Male                                        | 1 (2.9%)              | 38 (8.6%)               | Ref.         |         |
| Female                                      | 19 (55.9%)            | 134 (30.5%)             | 5.39, (0.70, 41.56) | 0.11    |
| Unknown                                     | 14 (41.2%)            | 268 (60.9%)             |              |         |
| **Contact with history of HFMD or herpangina** |                       |                         |              |         |
| Male                                        | 7 (20.6%)             | 173 (39.3%)             | Ref.         |         |
| Female                                      | 18 (52.9%)            | 144 (32.7%)             | 3.09, (1.26, 7.60) | 0.01    |
| Unknown                                     | 9 (26.5%)             | 123 (28.0%)             |              |         |

The p values were measured by Student’s t-test or chi-squared test. SD denotes standard deviation; HFMD, hand, foot and mouth disease; OR, odds ratio; CI, confidence interval; NA, not available.

https://doi.org/10.1371/journal.pone.0224110.t002
For the 6 to 15 year-old children, no significant risk factors were found except older age. For 16-50-year-old people, the significant risk factor associated with EV71 seropositivity was having children in addition to older age: 61% of seropositive 16-50-year-old people had children in their families but only 27% of seronegative 16-50-year-old people had children in their families ($p < 0.001$).

**Comparison of EV71 serostatus among 1997, 1999, 2007 and 2017**

Fig 2 shows age-specific seropositive rates among 1997, 1999, 2007 and 2017. Infants might have maternal antibodies, so they did not have significantly different seropositive rates among different years ($p = 0.62$). The rates in 2–11-year-old children were significantly lower in 2007 and 2017 than those rates in 1997 and 1999 ($p < 0.001$). The seropositive rate of the 6–19-year-olds in 2017 was significantly lower than those rates in 1997, 1999 and 2007 ($p < 0.001$). The seropositive rates of 20–to 29-year-old adults were not significantly different among the 4 different years.

https://doi.org/10.1371/journal.pone.0224110.g002

Discussion

This EV71 seroepidemiology study in 2017 shows that seropositive rates in children were significantly lower in comparison with those rates in 1999 [19,20], one year after the first epidemic occurred in Taiwan in 1998. The EV71 seropositive rates in 2017 were very low, at 4%
to 10%, in the very-high-risk group (<6-year-old preschool children) and not high, at 31%, in primary school students. The risk factors associated with seropositivity in preschool children included female gender, having siblings, more siblings, and contact with HFMD and/or HA whereas the only risk factor associated with seropositivity in adults was having children in the family in addition to older age.

The lower seropositive rates in young children observed in 2007 and 2017 correlate well with the fact that there were no major EV71 outbreaks during the last 10 years. Factors underlying the decreasing seropositivity may include lower birth rates and strict implementation of preventive measures during this time period [21]. The low birth rate and having only one child in most families in Taiwan make children get EV71 infection at an older age in comparison with the previous periods of the late 1990s or early 2000s. In our previous study conducted in 2001–2002, we found a very high EV71 household transmission rate of 84% among siblings if there were any siblings infected with EV71 in the household [22]. Taiwan has the sixth-lowest birth rate in the world, according to the most recent data released by the Central Intelligence Agent World Factbook [23], and the fertility rate in Taiwan was only 1.13 children per woman in 2017 and 1.218 children per woman in 2018, which was the third lowest in the world [23]. Because of having only one child in most families in recent years, there is no elder sibling(s) to spread viruses, including EV71, into the other family members; thus, most children acquire viral infection when they go to school or kindergarten. Therefore, the age of getting EV71 becomes older than in previous periods. In addition, EV71 infection at different ages has different symptomatic ratios and severity [19]. The symptomatic ratios are much lower [19], and the severity is milder when children get an EV71 infection at older ages [13, 24].

After the nationwide EV71 epidemic that occurred in Taiwan in 1998, multiple and real-time national enterovirus surveillance systems have been established by the Taiwan Centers for Disease Control since 2000 and include viral lab network; outpatient, inpatient, and emergency room visits for HFMD and/or HA from National Health Insurance claim data; and mandatory notification of enterovirus severe cases [13–16, 21]. The real-time EV surveillance makes early detection of EV71 possible, and strict implementation of preventive measures during EV71 circulation periods are applied, so these preventative measures may limit the spread of EV71 [21]. For example, to reduce the risk of enterovirus clustering, class suspension has been executed for the pre-school education and care institutions. Strengthened implementation of infection control measures is applied in hospitals and postpartum nursing care centers to reduce the risk of enterovirus clusters. For medical care of severe enterovirus cases, Taiwan Centers for Disease Control have constructed a medical service network for recent 2 decades and workshops are held on the clinical treatment of critical enterovirus complications to enhance doctors’ skills every year. There has been a marked decrease in severe and fatal EV71 cases after 2012 [17], and the results of this seroepidemiology study also endorse the impact of a well-established real-time enterovirus surveillance system and all the preventive measures to limit the spread of EV71 in Taiwan. Other speculations may include viral evolution, as evidenced by EV71-like gene elements appearing in other cocirculating EV-A viruses by intensive recombination [25]. The virulence of EV71 could thus be modified. Overall, the viral (recombination and mutation), host (low birth rate) and environmental (increased surveillance) factors might change transmission dynamics of EV71. However, with the accumulation of a susceptible high-risk group during the past 20 years, new epidemics could occur in the years to come. Careful monitoring and preventive measures are still necessary.

Risk factors associated with EV71 seropositivity were female gender, having siblings, more siblings, classmates with HFMD and/or HA and contact with HFMD and/or HA in high-risk groups. The seropositive rate in females is significantly greater than in males. However, the male-to-female ratio of symptomatic and/or severe enterovirus infections shifted toward
males and was approximately 1.5 [10,13,24]. The role of gender on the susceptibility to EV71 and the severity of EV71 infections remains unclear and needs further investigation.

Among different regions in Taiwan, 3- to 5-year-old children and primary school students in rural areas had greater seropositive rates. In our previous seroepidemiology conducted in 1999, living in rural areas was also a significant risk factor for EV71 infection [19]. The possible reasons may be poorer hygiene behaviors and larger family size, resulting in more possible contacts and transmissions of EV71 in rural areas. The socioeconomic and educational gaps between urban and rural areas might affect the parents’ and/or caregivers’ hygiene behavior, which would in turn have some impact on the infection incidence and/or severity. For example, caregivers in the critical group (encephalitis with or without cardiopulmonary failure) of EV71 infection had a significantly lower rate in terms of cleaning the faucet after washing their hands, as our previous study reported [24].

Young children in Taiwan have very low EV71 seropositive rates now and therefore harbor a high risk of developing an EV71 infection. Our earlier studies also showed that young children are at especially high risk of developing severe disease after EV71 infections [24]. Future EV71 vaccine policy should be targeted to young children, who will be the first priority to receive the EV71 vaccine in Taiwan.

For 16-50-year-old people, the significant risk factor associated with EV71 seropositivity was having children in addition to older age. Bidirectional transmission of EV71 between children and parents or other household adults does occur, parents or other household adults might transmit EV71 to their children and vice versa. For example, a Japanese mother developed encephalitis caused by intrafamilial transmission of EV71 from her 1-year-old son and it also elucidated the risk for EV71 encephalitis even in adults [26]. Therefore, parents and other household adults have to be cautious and take preventive measures once their children have such infection.

We further compared EV71 serostatus among different countries in Table 3. Among different countries, the EV71 seropositive rates varied greatly. The seropositive rates of children in China, Thailand and Cambodia were very high, ranging from 35 to 98% [27–31]. The rates (15 to 37%) of children in Singapore in 2008–2010 were comparable to those in Taiwan in 2007 and 2017 [28]. The rates in Russia varied in different regions: the rates were lower (5 to 19%) in urban areas, such as Moscow and Rostov, than those (20 to 83%) in rural areas, such as Tyva [29]. Severe EV71 cases occurred more frequently in countries, such as China and Cambodia which had greater seropositive rates [7, 23, 31–33] and it indicates greater disease burden in these countries. EV71 outbreak occurred in Cambodia in 2012, it characterized by severe encephalitis with cardiovascular collapse and pulmonary edema seized international headlines and resulted in the death of at least 54 children [31], and more than 2 thousands of laboratory-confirmed EV71 cases died in China from 2008 to 2015 [7].

There are some limitations in this study. First, the test population (sampling methods, geographical and demographical characteristics) were not the same with those previous studies of 1997, 1999 and 2007 in Taiwan although the laboratory method was the same. Second, the sample size of young children was small and the power may be limited, so larger sample size and multiple test correction may be needed in the future to verify our findings. Third, the EV71 viral strains used for neutralizing antibody, cut-off criteriae for seropositivity and the age groups are different among different countries. Although the seroprevalence rates were not so comparable, we tried our best to clarify the difference and did some important comparisons.

Conclusions

The EV71 seropositive rates were very low, at 4% to 10%, in the high-risk group (<6-year-old preschool children) and not high, at 31%, in primary school students. Female gender, having
siblings, more siblings and contact with HA or HFMD were factors associated with EV71 sero-
positivity in children younger than 6 years of age while having children in the family and older
age were factors associated with EV71 seropositivity in 16–50-year-old people. Young children
will be the group with the greatest priority to receive the EV71 vaccine.

The cutoff for EV71 seropositivity was $\geq 1:8$ [19, 27–30], except in the Cambodia study, which used a titer of $\geq 1:16$ as the cutoff [31].
NA: not available.
Numbers in parenthesis are case number with EV71 seropositivity/case number tested but those numbers are not available in Cambodia.

- The rate for children younger than 2 years [27].
- The rate for 1–6 year-old children [28].
- The rate for 1–2 year-old children [29].
- The rate for 6 month-old to 2 year-old children [30].
- The rate for 6 year-old children [31].
- The rate for 12 to 15 year-old adolescents [31].

https://doi.org/10.1371/journal.pone.0224110.t003

Supporting information

S1 File. Questionnaire for preschool children with Chinese-English parallel texts.
(PDF)

S2 File. Questionnaire for students with Chinese-English parallel texts.
(PDF)

S3 File. Questionnaire for adults with Chinese-English parallel texts.
(PDF)

Author Contributions

Conceptualization: Luan-Yin Chang.

Data curation: Jian-Te Lee, Ting-Yu Yen, Wei-Liang Shih, Yi-Chuan Huang, Tzou-Yien Lin.

Formal analysis: Wei-Liang Shih, Luan-Yin Chang.

Funding acquisition: Ding-Ping Liu, Luan-Yin Chang.
Investigation: Ting-Yu Yen.
Methodology: Ding-Ping Liu.
Resources: Luan-Yin Chang, Li-Min Huang.
Supervision: Chun-Yi Lu, Luan-Yin Chang, Li-Min Huang, Tzou-Yien Lin.
Validation: Wei-Liang Shih, Chun-Yi Lu, Ding-Ping Liu, Li-Min Huang, Tzou-Yien Lin.
Writing – original draft: Jian-Te Lee, Luan-Yin Chang.
Writing – review & editing: Ting-Yu Yen, Wei-Liang Shih, Chun-Yi Lu, Ding-Ping Liu, Yi-Chuan Huang, Luan-Yin Chang, Li-Min Huang, Tzou-Yien Lin.

References
1. Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974; 129:304–309. https://doi.org/10.1093/infdis/129.3.304 PMID: 4361245
2. Shindarov LM, Chumakov MP, Voroshilova MK, Bojinov S, Vasilenko SM, Iordanov I, et al. Epidemiological, clinical and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol. 1979; 23:284–295. PMID: 231067
3. Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982; 71:217–227. https://doi.org/10.1007/BF01314873 PMID: 6285858
4. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. Clin Infect Dis. 2000; 31:678–683. https://doi.org/10.1086/314032 PMID: 11017815
5. Centers for Diseases Control and Prevention. Deaths among children during an outbreak of hand, foot, and mouth disease—Taiwan, Republic of China, April-July 1998. MMWR Morb Mortal Wkly Rep. 1998; 47:629–632. PMID: 9704628
6. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010; 10(11):778–790. https://doi.org/10.1016/S1473-3099(10)70194-8 PMID: 20961813
7. Yang B, Liu F, Liao Q, Wu P, Chang Z, Huang J, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017; 22(50).
8. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. N Eng J Med. 1999; 341:929–935.
9. Wu TN, Tsai SF, Li SF, Lee TF, Huang TM, Wang ML, et al. Sentinel surveillance for enterovirus 71, Taiwan, 1998. Emerg Infect Dis. 1999; 5:458–460. https://doi.org/10.3201/eid0503.990321 PMID: 10341187
10. Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71 related hand, foot, and mouth disease. Lancet. 1999; 354:1682–1686. https://doi.org/10.1016/S0140-6736(99)04434-3 PMID: 10568570
11. Lin TY, Chang LY, Hsia SH, Huang YC, Chiu CH, Hsueh C, et al. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis. 2002; 34 Suppl 2:S52–S57.
12. Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY. Enterovirus 71 Outbreaks in Taiwan: Occurrence and Recognition. Emerg Infect Dis. 2003; 9:291–293. https://doi.org/10.3201/eid0903.020028 PMID: 12643822
13. Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT. An eight-year study of epidemiological features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg. 2007; 77:188–191. PMID: 17620632
14. Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998–2005. Pediatrics. 2007; 120:e244–252. https://doi.org/10.1542/peds.2006-3331 PMID: 17671037
15. Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol. 2008; 49:103–112. https://doi.org/10.1016/S1875-9572(08)60023-6 PMID: 19054914
16. Chia MY, Chiang PS, Chung WY, Luo ST, Lee MS. Epidemic of enterovirus 71 infections in Taiwan. Pediatr Neonatol. 2014; 55(4):243–249. https://doi.org/10.1016/j.pedneo.2013.07.007 PMID: 24120535
17. Liu DP, Wang TA, Huang WT, Chang LY, Wang ET, Cheng SH, et al. Disease burden of enterovirus infection in Taiwan: Implications for vaccination policy. Vaccine. 2016; 34(7):974–980. https://doi.org/10.1016/j.vaccine.2015.12.026 PMID: 26768128

18. Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Review of Vaccines. 2010; 9:149–156. https://doi.org/10.1586/erv.09.152 PMID: 20109026

19. Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002; 109:e86. https://doi.org/10.1542/peds.109.6.e86 PMID: 12045282

20. Lu CY, Lee CY, Kao CL, Shao WY, Lee PI, Twu SJ, et al. Incidence and case–fatality rates resulting from the 1998 enterovirus 71 outbreak in Taiwan. J Med Virol. 2002; 67:217–223. https://doi.org/10.1002/jmv.2210 PMID: 11992582

21. Jian SW, Chen CM, Lee CY, Liu DP. Real-Time surveillance of infectious diseases: Taiwan’s experience. Health Secur. 2017; 15(2):144–153. https://doi.org/10.1089/hs.2016.0107 PMID: 28418738

22. Chang LY, Tsao KC, Hsia SH, Shih SR, Huang CG, Chan WK, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. 2004; 291:222–227. https://doi.org/10.1001/jama.291.2.222 PMID: 14722149

23. Central Intelligence Agent. The world Fact Book-country comparison: birth rate. [cited 2018 Dec 20]. https://www.cia.gov/library/publications/resources/the-world-factbook/fields/345rank.html

24. Huang WC, Shih WL, Yang SC, Yen TY, Lee JT, Huang YC, et al. Predicting severe enterovirus 71 infection: age, comorbidity, and parental behavior matter. J Microbiol Immunol Infect. 2017; 50:10–16. https://doi.org/10.1016/j.jmi.2014.11.013 PMID: 25678038

25. Lee KM, Gong YN, Hsieh TH, Woodman A, Dekker NH, Cameron CE, et al. Discovery of Enterovirus A71-like nonstructural genomes in recent circulating viruses of the Enterovirus A species. Emerg Microbes Infect. 2018; 7(1):111. https://doi.org/10.1038/s41426-018-0117-0 PMID: 29930332

26. Hamaguchi T, Fujisawa H, Sakai K, Okino S, Kurosaki N, Nishimura Y, et al. Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult. Emerg Infect Dis. 2008; 14(5):828–30. https://doi.org/10.3201/eid1405.071121 PMID: 18439374

27. Zhang D, Chen Y, Chen X, He Z, Zhu X, Hao Y. Enterovirus 71 neutralizing antibodies seroepidemiological research among children in Guangzhou, China between 2014 and 2015: a cross-sectional study. Int J Environ Res Public Health. 2017; 14:319.

28. Ang LW, Tay J, Phoon MC, Hsu JP, Cutter J, James L, et al. Seroepidemiology of coxsackievirus A6, coxsackievirus A16, and enterovirus 71 infections among children and adolescents in Singapore, 2008–2010. PLoS One. 2015; 10:e0127999. https://doi.org/10.1371/journal.pone.0127999 PMID: 26011735

29. Akhmadishina LV, Eremeeva TP, Trotsenko OE, Ivanova OE, Mikhailov MI, Lukashev AN. Seroepidemiology and molecular epidemiology of enterovirus 71 in Russia. PLoS One. 2014; 9:e97404. https://doi.org/10.1371/journal.pone.0097404 PMID: 24819617

30. Linsuwanon P, Puenpa J, Huang SW, Wang YF, Mauleekoonphairoj J, Wang JR, et al. Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations. J Biomed Sci. 2014; 21:16. https://doi.org/10.1186/1423-0127-21-16 PMID: 24548776

31. Horwood PF, Andronic A, Tarantola A, Saije H, Duong V, Mey C, et al. Seroepidemiology of human enterovirus 71 infection among children, Cambodia. Emerg Infect Dis. 2016; 22:92–95 https://doi.org/10.3201/eid2201.151323 PMID: 26690000

32. Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014; 14:308–318. https://doi.org/10.1016/S1473-3099(13)70342-6 PMID: 24485991

33. Duong V, Mey C, Elot M, Zhu H, Danet L, Huang Z, et al. Molecular epidemiology of human enterovirus 71 at the origin of an epidemic of fatal hand, foot and mouth disease cases in Cambodia. Emerg Microbes Infect. 2016; 5:e104. https://doi.org/10.1038/emi.2016.101 PMID: 27651091